U.S. House Judiciary Chairman Bob Goodlatte (R-VA) has sent letters to the American Bar Association and every state bar association, urging the organizations to adopt requirements for warnings on trial lawyer advertisements that urge patients to discontinue the use of some medicines. Read More »
U.S. Congressmen Doug Collins (R-GA) and Dave Loebsack (D-IA) last week introduced a bill -- H.R. 1316, the Prescription Drug Price Transparency Act -- that they say would "require greater transparency from pharmacy benefit managers (PBMs)." In introducing the bill, the congressmen, along with Rep. Buddy Carter (R-GA) and others, took to the House floor to deliver what Drug Channels' Dr. Adam Fein referred to as a "60-minute rant" against PBMs. Read More »
According to a recent PRNewswire release, CVS Pharmacy is the first national retail pharmacy chain to remove trans fat from their store brand food products. Read More »
CVS Health Research Institute recently released a statement on its decision to stop selling tobacco products and the research behind that decision. Read More »
The Association for Accessible Medicines (AAM) recently announced that its president and CEO, Chip Davis, made a statement regarding the confirmation of Tom Price as Secretary of Health and Human Services. Read More »
Prime Therapeutics releases report showing it held drug costs increases to just 2.5 percent for its clients in 2015. Read More »
"I'm thankful that we have the PBMs in the Part D program that are performing that negotiation on behalf of seniors." -- Seema Verma, nominee to serve as administrator of the Centers for Medicare and Medicaid Services Read More »
The listed price for brand-name drugs increased 11 percent last year, but the largest pharmacy benefits manager in the U.S. said it shielded employers it works with from the bulk of that increase. Read More »
Pharmaceutical companies, trial lawyers and tort reform advocates are closely following a case that the U.S. Supreme Court has taken up that addresses the issue of plaintiffs joining suits in other states. Read More »
Nationwide mail-order pharmacy giant Express Scripts recently revealed successful limits to 2016 drug spending — yielding a 27 percent decrease over that of 2015 — from St. Louis as it released its annual Drug Trend Report. Read More »
In a letter sent to the U.S. House of Representatives, leaders from Americans for Tax Reform, Citizens Against Government Waste, and the National Taxpayers Union, urged congressional members to "oppose any attempts to change the successful and cost-saving process by which drug prices are negotiated for Medicare Part D." Read More »
As the Trump Administration and new Congress signal their intent to somehow deal with the issue of rising prescription drug prices, the notion of giving the federal government more power to negotiate drug prices in Medicare Part D has been suggested as one measure that might be implemented. Two leading experts this week, however, threw cold water on that proposal, noting that such negotiations already exist and serve to bring down drug costs. Read More »
ABBV-8E 12 -- a new Alzheimer’s treatment still in development -- received a fast-track designation from the U.S. Food and Drug Administration to be moved to clinical trials. Read More »
The rate of kidney failure related to diabetes among Native American adults dropped more than 50 percent between 1996 and 2013, the Centers for Disease Control and Prevention reported recently. Read More »
A clear plurality (almost half) of American consumers blame drug makers for high drug costs, according to a new Google Consumer Survey conducted for American Pharmacy News. Read More »
Dealing with the thorny, and often contentious, issue of drug prices is likely to be front and center in the early days of the new Trump administration. Arriving at a solution to curb increasing costs will be a delicate balance for all those with a stake in the issue, according to a leading health economist. Read More »
Following recent public reaction to the price of epinephrine auto-injector pens, known as “epi-pens,” and the desire for an affordable alternative, CVS Health intends to market authorized generic version two-packs for $109.99 apiece. Read More »
A recent study has shown that medical home care model as increased overall primary care of patients, and has reduced overall health care cost. Read More »
The public relations departments at American pharmaceutical manufacturers can’t be too pleased about the results of a new Harris Poll out this week that shows only nine percent of U.S. consumers believe “pharmaceutical and biotechnology companies put patients over profits.” Read More »
Two pharmaceutical giants — Sanofi and Regeneron — face a forced marketing shutdown of a high-priced cholesterol medication following a decision recently handed down by a U.S. District Court in Delaware ruling patent infringement of another medication. Read More »
Alerts Sign-up
